Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

0.9238 +0.0186 (+2.05%)
Official Closing Price Updated: 8:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
The Three Best Anti-Aging Stocks to Buy in September
These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments 
Via InvestorPlace
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78... 
Via Benzinga
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Recap: Lineage Cell Therapeutics Q2 Earnings
  Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics: Q1 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: Lineage Cell Therapeutics
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Insiders Buying These 4 Penny Stocks
The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Insiders Buy Over $1.3M Of 4 Penny Stocks
The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last... 
Via Benzinga
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.